Deep Muscularis Propria Tumor Invasion Without Lymph Node Metastasis as a Unique Subclassification of Stage IB Gastric Cancer: A Retrospective Study

Kang He
The Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research

Cheng Chen
The Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research

Lei Xia
The Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research

Lixiang Si
The Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research

Xiaohua Pan
The Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research

Zijian Sun
The Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research

Yajing Wang
The Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research

Yingying Jiang
The Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research

Yue Shi
The Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research

Bin Zhou
The Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research
Research Article

Keywords: deep muscularis propria, superficial muscularis propria, stage IB gastric cancer, p53, serum tumor marker, prognosis

Posted Date: October 8th, 2021

DOI: https://doi.org/10.21203/rs.3.rs-664586/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Background

The prognosis difference based on the depth of tumor muscularis propria invasion in gastric cancer (GC) was still debated.

Methods

A total of 380 patients with pT2 GC after radical surgery were retrospectively analyzed, including 185 in superficial muscularis propria (sMP) group and 195 in deep muscularis propria (dMP) group.

Results

The overall survival (OS) was significantly better for patients in sMP group than for patients in dMP group (P=0.007). In multivariate analysis, depth of tumor invasion, pN stage, age, primary location, positive expression of p53, elevated maximal LDH, elevated initial CA19-9 and AFP level were independent prognostic factors for OS. The sMP group had a significantly better OS than dMP group (P=0.014) in pN0 stage. After further stratification, the survival outcomes were not significantly different between deep muscularis propria tumor invasion without lymph node metastasis (dMPN0) group (stage IB) and superficial muscularis propria tumor invasion with stage 1-2 lymph node metastasis (sMPN1-2) group (stage II) (P=0.100). Patients with adjuvant chemotherapy had a statistically better survival than those without in dMPN0 group (P=0.045) and dMPN0 patients with adjuvant chemotherapy had better OS than sMPN1-2 patients (P=0.015). In addition, greater postoperative survival could be observed in sMPN0 patients than dMPN0 patients in p53-positive group (P=0.002), and similar OS could be seen between dMPN0 patients with p53-positive and T2N1-2 patients (P=0.872).

Conclusion

As a unique subclassification of stage IB GC, appropriate adjuvant chemotherapy should be considered for patients with dMPN0 stage. In addition, positive expression of p53, elevated LDH could be potential factors in identifying the different prognoses for stage IB GC patients.

Introduction

Gastric cancer (GC) is the third commonest malignant disease and the fourth most frequent cause of cancer-related deaths in the world. With the growing progression of the medical technology and the improvement of health consciousness, the incidence of gastric cancer declined steadily, however, the prognoses of advanced GC patients are still pessimistic with a 5-year overall survival rate of 25-30%[1, 2].
Accurate staging of gastric cancer is the basis for guiding treatment strategy and judging the prognosis of patients. TNM staging system introduced by the Union for International Cancer Control/American Joint Committee on Cancer (UICC/AJCC) is adopted internationally in recent years. However, in clinical practice, the prognosis for pT2 staging GC, a variant of advanced gastric cancer, is diverse, which could not be simply explained by the TNM staging and postoperative therapy regimens. In general, the muscularis propria of the stomach is histologically subdivided further into two layers: the inner circular layers, and outer longitudinal layers. In addition, the newest edition of TNM stage system does not specify details for definition of subclassification of pT2 stage (sMP vs dMP). Therefore, we believe that it is reasonable to consider that the subclassification of the pT2 stage can be used as a new standard for prognostic prediction and clinical decision-making.

The prognosis for gastric cancer differs widely even among patients with the same tumor stage and grade. The TNM classification does not completely differentiate good and bad prognosis of individual patients. Therefore, there is an urgent need for new biomarkers, such as serum tumor markers and gene mutations, improving the assessment accuracy of the pTNM staging and tumor aggressiveness. Currently, it is thought that the accumulation of mutated genes results in GC tumorigenesis, and several gene mutations, such as p53, HER-2, EGFR, VEGF, have been proved to be correlative with the prognosis of gastric cancer in several studies. In addition, serum tumor markers, like carcinoembryonic antigen (CEA), lactate dehydrogenase (LDH), carbohydrate associated antigen 19-9 (CA19-9), cancer antigen 125 (CA125) and alpha-fetoprotein (AFP), are more convenient and cost-effective detections than other approaches, they are extensively used in monitoring disease condition, assessing treatment effect, estimating prognosis and predicting recurrence[3].

Above all, we conduct present study to identify the relations between subclassification of pT2 gastric cancer and survival outcomes and clinicopathological features according to the depth of tumor involvement, and further analyze potential markers to reinforce the prognostic and therapy-guided ability of the TNM staging system.

**Materials And Methods**

**Ethics Statement**

The study was approved by the clinical research ethics committee of the Jiangsu Cancer Hospital and was conducted in accordance with the Declaration of Helsinki.

**Patients**

A total of 2810 patients underwent curative gastrectomy between January 1,2008 and December 31,2014 were retrospectively collected from our institutes. The inclusion criteria were: 1) a tumor pathologically diagnosed as gastric adenocarcinoma; 2) patients who accepted radical gastrectomy (R0) and pathologically were confirmed as pT2N0–3M0 stages according to the 8th edition TNM staging system.
(UICC/AJCC); 3) clinicopathological data and follow-up information were complete. The exclusion criteria were: 1) patients with a history of distant metastases and/or other malignant diseases; 2) patients who accepted preoperative chemotherapy and/or radiotherapy; 3) tumors that were pathologically confirmed as neuroendocrine tumors or contained neuroendocrine components. Detailed flow chart for selection process could be seen in Figure 1. Finally, 380 patients who met the inclusion but the exclusion criteria were analyzed in our study. Patients were separated into the sMP group and the dMP group based on the tumor involvement depth by two pathologists. In line with previous study[4], the sMP was defined as the maximal invasive depth of tumor to the superficial half part of the MP layer (inner circular muscle bands), while the dMP was defined as the maximal invasive depth of tumor to the deep half part of the MP layer (outer longitudinal muscle bands).

Therapy strategy

According to the treatment guidelines and preoperative examination (radiological imaging tests and pathological tests), patients who matched surgical indications in our hospital underwent gastrectomy with standard lymph node dissection. The decision as to whether patients received postoperative adjuvant chemotherapy depended on the integrated evaluation of pathological examination, therapy guideline and patient intention. Adjuvant chemotherapy regimens were single-agent fluoropyrimidine or platinum combined with fluoropyrimidine.

Immunohistochemistry

Immunohistochemistry (IHC) were performed as previously described[5, 6], detailed experimental steps were as follows. Four-micrometer-thick sections were obtained from formalin-fixed, paraffin-embedded tumor tissues. Tumor sections were deparaffinized in xylene and rehydrated through graded alcohols. Gastric slides were immersed and heated in a 0.01M sodium citrate buffer (pH 6.0) at 121°C for 2 min to repair antigens. Endogenous peroxidase activity was blocked through immersing the slides in 3% hydrogen peroxide for 10 min. The slides were then washed 3 times for 3 min each time with phosphate buffered saline (PBS). Tissue samples were finally exposed in non-immune horse serum for 30 min to reduce non-specific binding. The primary antibody was monoclonal mouse anti-human antibody (Do-7, Dako, Denmark, 1:100) for p53, monoclonal rabbit anti-human antibody (MXR001, MXB-BIO, China, 1:100) for HER-2, monoclonal rabbit anti-human antibody (EP22, MXB-BIO, China, 1:100) for EGFR, monoclonal mouse anti-human antibody (VG1, MXB-BIO, China, 1:100) for VEGF. Sections were incubated with the primary antibody overnight at 4°C, then incubated with a secondary antibody for 30 min at room temperature. After further washes in PBS, a diaminobenzidine tetrahydrochloride (DAB) solution was applied for visualization. Finally, the sections were counterstained with hematoxylin. Sample of positive-stained gastric cancer was served as positive control and PBS was used as a negative control. HER-2 scores were calculated according to Hofmann et al.’s criteria[7], HER2 positivity in the present study was
defined as an IHC score of 2+ and 3+. In addition, EGFR and VEGF staining were interpreted as positive when >10% of the tumor cells stained and p53 when >30% showed distinct nuclear staining.

**Study parameters**

Clinicopathologic features include gender (male, female), age (≤60, >60), smoking history (yes, no), drinking history (yes, no), ECOG score (0-2), location of primary tumor (upper, middle and lower), Borrmann type (Type I-II, III-IV), pathological type (adenocarcinoma, mucinous/rare carcinoma), histologic type (well and moderate, poor), neural invasion (negative, positive), lymphovascular invasion (negative, positive), pN stage (N0-N3), TNM stage (I-IIIA), adjuvant chemotherapy (without, with). Molecular markers including HER-2/neu, p53, VEGF, EGFR (negative, positive). Initial tumor markers were detected within seven days before surgery and maximal LDH was defined as the maximum of LDH during follow-up. The cut-off value of LDH, CEA, CA125, CA19-9 and AFP levels were 245 U/L, 3.5 ng/ml, 35 U/ml, 39 U/ ml and 7 ng/ml. Pathological tumor staging was based on the TNM staging system of UICC/AJCC (eighth edition).

**Statistics**

Continuous and categorical variables were assessed through the t-test, Chi-squared test or Fischer's exact test, separately. Kaplan–Merrier method and log-rank test were performed to distinguish univariate survival outcomes. Cox's proportional hazard model was used to identify significant prognostic factors. Statistical differences were considered as significant at two-sided P values < 0.05. All statistical analyses were estimated through SPSS software (version 22, Chicago, IL, USA).

**Results**

**Patients’ characteristics**

Finally, 185 patients in the sMP group and 195 patients in the dMP group were retrospectively analyzed. For clinicopathological factors, neural invasion, and elevated initial AFP level were more likely to appear in patients in the dMP group compared with the sMP group (P=0.010, P=0.005, respectively). There were lower number of lymph node metastases in the sMP group than dMP group (1.0±2.1 vs 1.6±2.7, P=0.027). There were no obvious differences in sex (P=0.557), age (P=0.539), smoking history (P=0.273), drinking history (P=0.685), ECOG score (P=0.334), primary tumor location (P=0.896), Borrmann type (P=0.888), pathological type (P=0.589), histology type (P=0.836), lymphovascular invasion (P=0.271), pN stage (P=0.205), pTNM stage (P=0.105), number of retrieved lymph node (14.7±6.8 vs 14.5±6.7, P=0.889) and postoperative adjuvant chemotherapy (P=0.138) between the sMP and dMP groups. For molecular markers, the expression of HER-2/neu, p53, VEGF and EGFR were similar in two groups (P=0.252, P=0.236, P=0.315, P=0.262, respectively). There was no statistical significance in serum tumor markers.
such as initial and maximal LDH level, initial CEA, CA125 and CA19-9 level between the two groups (P=0.693, P=0.165, P=0.263, P=0.132, P=0.126, respectively). Detailed information was shown in Table 1.

**Survival analysis**

By December 31, 2020, 10 of the 390 cases were lost to follow up during the follow-up. The follow-up period ranged from 2-166 months with a median follow-up duration of 99 months. For survival outcomes, patients in sMP group had a statistically better 5-year OS rate than those in dMP group (91% vs 84%, P=0.007) (Figure 2).

Univariate and multivariate survival analyses were used to find prognostic factors (Table 2). Depth of tumor invasion, pN category, age, primary tumor site, neural invasion, positive expression of p53, elevated maximal LDH level, elevated initial CA19-9, CEA and AFP level were statistical prognostic factors in the univariate analysis. Multivariate Cox regression analysis confirmed that depth of tumor invasion, pN category, age, primary tumor site, positive expression of p53, elevated maximal LDH level, elevated initial CA19-9 and AFP level were independent prognostic factors.

For patients stratified as pN0 stage, significantly better postoperative survival could be observed in sMP group than dMP group (95% vs 91%, P=0.014) (Figure 3A). For patients classified as pN+, there was no obvious differences in the postoperative survival between two groups (80% vs 74%, P=0.384) (Figure 3B). When patients were stratified based on the tumor invasion depth and pN stage, the 5-year OS was no significant difference between the deep muscularis propria tumor invasion without lymph node metastasis (dMPN0) group and superficial muscularis propria tumor invasion with stage 1-2 lymph node metastasis (sMPN1-2) group (92% vs 82%, P=0.100) (Figure 4A). The 5-year OS of patients with the adjuvant chemotherapy were statistically better than those without the adjuvant chemotherapy in the dMPN0 group (93% vs 89%, P=0.045) (Figure 4B), but not significantly better in the sMPN1-2 group (P=0.486) (Figure not shown). After further subgroup according to the adjuvant chemotherapy status, in comparison to the sMPN1-2 patients, the dMPN0 patients with the adjuvant chemotherapy had better postoperative survival (81% vs 93%, P=0.015) (Figure 4C), but not significantly better in patients without the adjuvant chemotherapy (81% vs 89%, P=0.599) (Figure 4D).

Furthermore, upon stratification of groups according to the expression of p53, in the p53-positive group, greater survival outcomes could be observed in patients with sMPN0 than patients with dMPN0 (97% vs 84%, P=0.002) (Figure 5A). After further comparison, similar survival outcomes could be seen between the dMPN0 patients with p53-positive and the muscularis propria tumor invasion with stage 1-2 lymph node metastasis (T2N1-2) patients (84% vs 80%, P=0.872) (Figure 5B). After grouping according to the level of maximal LDH, in the elevated maximal LDH level group, sMPN0 patients had a higher 5-year OS than dMPN0 patients (96% vs 89%, P=0.029) (Figure 5C). There was no significant difference of the 5-year OS between the dMPN0 patients with elevated maximal LDH level and T2N1-2 patients (89% vs 80%, P=0.514) (Figure 5D). Similarly, in elevated initial CEA level group, sMPN0 patients had a better 5-year OS than dMPN0 patients (96% vs 86%, P=0.011) (Figure 5E). Insignificant difference of the 5-year OS could
be seen between the dMPN0 patients with elevated initial CEA level and T2N1-2 patients (87% vs 80%, P=0.935) (Figure 5F). The survival outcomes of patients with sMPN0 and dMPN0 were not significantly different in the p53 negative-expression group, normal LDH group and CEA groups.

**Discussion**

Despite the incidence rate of the gastric cancer has been continuously decreasing during the past decade, it remains the third most common cancer type worldwide. With the rapid improvement of medical science, many indicators are established to calculate the aggressiveness and severity of gastric cancer. For example, as a critical method for prognosis of the gastric cancer patients after radical surgery, the TNM staging system, is widely acknowledged by clinical physicians. Nevertheless, the survival outcomes for patients with the advanced gastric cancer varies widely even in the same disease stage, similar situation can also be seen in pT2 stage. For one thing, the data about clinicopathological characteristics and survival outcomes for pT2 stage gastric cancer patients after radical surgery is limited. For another, it is obvious that cancer aggressiveness, distant metastasis risk and patient prognosis are nearly correlated to the tumor infiltration in gastric cancer[8], and the latest 8th TNM staging system does not define the detailed subclassification of the pT2 stage. Above all, it is necessary to investigate prognostic differences based on the depth tumor muscularis propria infiltration.

For all we know, this is the first study to evaluate differences in the clinicopathologic features and the prognoses of pT2 subclassification based on the depth of tumor muscularis propria infiltration in a large cohort of Chinese gastric cancer patients. Molecular markers and serum tumor markers also are firstly investigated in the pT2 subclassification.

Several studies that discussed the clinicopathological features and survival difference for pT2 stage GC used the older stage system, that contained tumors subserosa invasion stage[4, 9, 10]. On the contrary, our present study was based on the latest staging system that only included tumors invading the muscularis propria, patients were allocated into two groups, the sMP group and dMP group. For general characteristics, there were more regional lymph node metastases in patients of the dMP group than patients of the sMP group, which in line with the previous study[4, 11]. We also found that neural invasion and elevated initial AFP levels were more likely to appear in the dMP group than the sMP group.

In previous studies, Sun and colleagues[4] demonstrated that patients in the sMP group had significantly better survival outcomes than patients in the dMP/SS group, whereas similar outcomes could be observed in the dMP group and the SS group. However, they did not analyze the prognosis differences among the sMP group and dMP group. We demonstrated that in N0 group, patients with sMP tumor had statistically longer survival than patients with dMP tumor, but not in N+ group. This result is consistent with the findings of Zhang and colleagues[11]. In addition, when patients were grouped depending on the depth of tumor invasion and pN stage, we further found that the survival outcomes were not significantly different between patients with the dMPN0 stage and with the sMPN1-2 stage. After further comparison according to postoperative adjuvant chemotherapy status, we observed that significantly improved
survival outcomes for patients who had received the adjuvant chemotherapy in the dMPN0 staging group, rather than in the sMPN1-2 staging group. We also observed that the dMPN0 patients with the adjuvant chemotherapy had a better postoperative survival compared to sMPN1-2 patients.

Depending on the latest 8th UICC/AJCC TNM staging system, sMPN0, dMPN0 patients and sMPN1-2 patients were classified as stage IB, IB and II, respectively, and patients with stage II, rather than with stage IB, should receive the adjuvant chemotherapy depending on therapy guideline. In the present study, however, significantly different survival could be seen between sMPN0 group (stage IB) and dMPN0 group (stage IB), but not dMPN0 group (stage IB) and sMPN1-2 group (stage II), and dMPN0 patients who received the adjuvant chemotherapy had obviously improved postoperative survival compared to sMPN1-2 patients. These results showed that the dMPN0 stage should be divided from stage IB as a special subclassification and the dMPN0 patients should receive appropriate adjuvant chemotherapy and follow-up strategy.

As the increase in the understanding of the molecular mechanism of tumorigenesis, it is currently believed that the molecular markers related with the tumorigenesis and disease progression may be potential prognostic factors. The mutated p53 gene subsequently causing inactivation of the p53 protein tumor-suppressor activity appear to constitute one of the commonest molecular steps in tumor development[12, 13]. It is reported that the gene mutation of p53 lead to an increased stability and prolonged half-life time of p53 protein, and result in a nuclear accumulation of protein where it is easily detectable by immunohistochemistry (IHC) using monoclonal antibodies[14]. Although the p53 protein accumulation detected by IHC does not entirely indicate the mutation of gene, the high accordance (85%) could be seen in the p53 overexpression and an underlying mutation[15]. Therefore, the p53 protein overexpression detected through IHC may be considered as a cheaper substitution of that gene mutation. Multiple studies also show the overexpression of the p53 protein as an indicator of poor prognosis in GC[5, 16, 17]. A previous meta-analysis[16], which collected 34 articles focusing on the prognostic value of p53 protein, suggested that positive/high p53 protein expression as a powerful biomarker to predict poorer survival outcomes for gastric cancer patients. Surprisingly, we found that almost all previous studies[5, 16, 17] that discussed the prognostic value of p53 had not performed subgroup analysis based on a certain TNM staging. In our study, we demonstrated that positive expression of p53 protein was a negative prognostic factor for the OS in the early stages of GC. Specifically, for patients with p53-positive, the sMPN0 group had better survival outcomes than dMPN0 group. Moreover, similar survival outcomes could be seen between the dMPN0 patients (stage IB) with p53-positive and T2N1-2 patients (stage II). The above results might unveil that dMPN0 patients (stage IB) with positive expression of p53 should accept suitable adjuvant chemotherapy like patients in stage II.

HER-2/neu as a predictive factor for the therapeutic effect of trastuzumab in the treatment of gastric cancer already has been confirmed by ToGA study[18]. However, the prognostic value of HER-2/neu for GC was still debated. Several studies reported overexpression of HER-2/neu protein as a predictor for aggressive tumor behavior and poor prognosis[19, 20], while others were not[21, 22]. In a meta-analysis[23], Pyo and colleagues found that HER2 IHC was highly concordant with ISH in HER2 IHC score
0/1+ or 3+ (96.9%, 91.5%, respectively) and lowly concordant with ISH in HER2 IHC score 2+ (39.3%). In our study, overexpression of HER-2/neu protein was not an adverse prognostic predictor. That discrepancy may be partly blamed for the low specificity of immunohistochemical in HER2 IHC score 2+ and the evaluation standard that defined the IHC score of 2+ and 3+ as HER-2 positivity in our study.

Prognostic value of serologic tumor markers was also been investigated in pT2 GC patients. We demonstrated that the elevated maximal LDH level, elevated initial CA19-9 and AFP level were poor prognostic factors in the multivariable survival analysis, which was concordant with previous studies[3, 24, 25]. Petrelli et al.[26] used a meta-analysis and confirmed that a high serum LDH concentration (>245 U/L) was associated with a poorer survival in the GC patients. Fanotto et al.[27] found similar results. After further subgroup analysis, we noticed that patients with the sMPN0 had a higher overall survival than those with the dMPN0 in the elevated maximal LDH level group and there was similar OS between the dMPN0 patients with the elevated maximal LDH level and T2N1-2 patients. Similar results also were shown in the dMPN0 patients with elevated maximal CEA levels. According to the above conclusions, we confirmed that serologic tumor markers could be used to identify individual heterogeneity and improve the survival prediction ability of the TNM staging.

Despite some promising findings, our present study still has several limitations. On the one hand, although the sample size of this study is the largest amongst other studies focusing on the T2 subclassification to date, as a single center retrospective study, the results are susceptible to selection bias. Further multi-center, large-sample, prospective studies are therefore required to verify the findings of this study. On the other hand, IHC has been applied to detect molecular markers of cancer in our present study. However, the differences of the types of antibody, concentration and evaluation standard of positivity used in IHC might produce potential bias.

**Conclusion**

As a unique subclassification of stage IB GC, appropriate adjuvant chemotherapy should be considered for patients with dMPN0 stage. In addition, positive expression of p53, elevated LDH could be potential factors in identifying the different prognoses for stage IB GC patients.

**Declarations**

**Ethics approval and consent to participate**

The study was approved by the clinical research ethics committee of the Jiangsu Cancer Hospital and was conducted in accordance with the Declaration of Helsinki, informed consent from all patients was obtained verbally and confirmed by the clinical research ethics committee of the Jiangsu Cancer Hospital.

**Consent for publication**
Availability of data and materials
All data generated or analyzed during this study are included in this published article. The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Competing interests
The authors declare that they have no competing interests.

Funding
This study was supported by the program of Jiangsu Cancer Research (ZN201605), and the general program of Jiangsu Commission of Health (H2017034).

Authors' contributions
KH collected the data and wrote the paper, CC, LX, BS and GRZ collected the data, XHW and JWL reviewed the paper, LXS, XHP, ZJS and YJW developed the methodology, YYJ, YS, BZ, SYW and JH analyzed the study data through statistics software.

Acknowledgements
Not applicable

References
1. De Angelis R, Sant M, Coleman MP, Francisci S, Baili P, Pierannunzio D, et al. Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE-5-a population-based study. The Lancet Oncology. 2014;15(1):23-34.
2. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA: a cancer journal for clinicians. 2014;64(1):9-29.
3. Shimada H, Noie T, Ohashi M, Oba K, Takahashi Y. Clinical significance of serum tumor markers for gastric cancer: a systematic review of literature by the Task Force of the Japanese Gastric Cancer Association. Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association. 2014;17(1):26-33.
4. Sun Z, Zhu GL, Lu C, Guo PT, Huang BJ, Li K, et al. A novel subclassification of pT2 gastric cancers according to the depth of muscularis propria invasion: superficial muscularis propria versus deep muscularis propria/subserosa. Annals of surgery. 2009;249(5):768-75.
5. Sawada T, Yashiro M, Sentani K, Oue N, Yasui W, Miyazaki K, et al. New molecular staging with G-factor supplements TNM classification in gastric cancer: a multicenter collaborative research by the
Japan Society for Gastroenterological Carcinogenesis G-Project committee. Gastric cancer: official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association. 2015;18(1):119-28.

6. Birkman EM, Ålgars A, Lintunen M, Ristamäki R, Sundström J, Carpén O. EGFR gene amplification is relatively common and associates with outcome in intestinal adenocarcinoma of the stomach, gastro-oesophageal junction and distal oesophagus. BMC cancer. 2016;16:406.

7. Hofmann M, Stoss O, Shi D, Büttner R, van de Vijver M, Kim W, et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology. 2008;52(7):797-805.

8. Zhang WH, Chen XZ, Liu K, Chen XL, Yang K, Zhang B, et al. Outcomes of surgical treatment for gastric cancer patients: 11-year experience of a Chinese high-volume hospital. Medical oncology (Northwood, London, England). 2014;31(9):150.

9. Marchet A, Mocellin S, Ambrosi A, Morgagni P, Vittimberga G, Roviello F, et al. Validation of the new AJCC TNM staging system for gastric cancer in a large cohort of patients (n = 2,155): focus on the T category. European journal of surgical oncology: the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. 2011;37(9):779-85.

10. Nitti D, Marchet A, Mocellin S, Rossi GM, Ambrosi A, Mencarelli R. Prognostic value of subclassification of T2 tumours in patients with gastric cancer. The British journal of surgery. 2009;96(4):398-404.

11. Zhang WH, He D, Chen DN, Li TT, Chen XZ, Yang K, et al. Comparison between superficial muscularis propria and deep muscularis propria infiltration in gastric cancer patients: A retrospective cohort study. Medicine. 2016;95(29):e4165.

12. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science (New York, NY). 1991;253(5015):49-53.

13. Lane DP. The regulation of p53 function: Steiner Award Lecture. International journal of cancer. 1994;57(5):623-7.

14. Ireland AP, Clark GW, DeMeester TR. Barrett's esophagus. The significance of p53 in clinical practice. Annals of surgery. 1997;225(1):17-30.

15. Baas IO, Mulder JW, Offerhaus GJ, Vogelstein B, Hamilton SR. An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms. The Journal of pathology. 1994;172(1):5-12.

16. Wei K, Jiang L, Wei Y, Wang Y, Qian X, Dai Q, et al. The prognostic significance of p53 expression in gastric cancer: a meta-analysis. Journal of cancer research and clinical oncology. 2015;141(4):735-48.

17. Joypaul BV, Hopwood D, Newman EL, Qureshi S, Grant A, Ogston SA, et al. The prognostic significance of the accumulation of p53 tumour-suppressor gene protein in gastric adenocarcinoma. British journal of cancer. 1994;69(5):943-6.

18. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive...
advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet (London, England). 2010;376(9742):687-97.

19. Kim KC, Koh YW, Chang HM, Kim TH, Yook JH, Kim BS, et al. Evaluation of HER2 protein expression in gastric carcinomas: comparative analysis of 1,414 cases of whole-tissue sections and 595 cases of tissue microarrays. Annals of surgical oncology. 2011;18(10):2833-40.

20. Wang YY, Ye ZY, Li L, Zhao ZS, Shao QS, Tao HQ. ADAM 10 is associated with gastric cancer progression and prognosis of patients. Journal of surgical oncology. 2011;103(2):116-23.

21. Yu GZ, Chen Y, Wang JJ. Overexpression of Grb2/HER2 signaling in Chinese gastric cancer: their relationship with clinicopathological parameters and prognostic significance. Journal of cancer research and clinical oncology. 2009;135(10):1331-9.

22. Song HS, Do YR, Kim IH, Sohn SS, Kwon KY. Prognostic significance of immunohistochemical expression of EGFR and C-erbB-2 oncoprotein in curatively resected gastric cancer. Cancer research and treatment. 2004;36(4):240-5.

23. Pyo JS, Sohn JH, Kim WH. Concordance rate between HER2 immunohistochemistry and in situ hybridization in gastric carcinoma: systematic review and meta-analysis. The International journal of biological markers. 2016;31(1):e1-10.

24. Li F, Li S, Wei L, Liang X, Zhang H, Liu J. The correlation between pre-operative serum tumor markers and lymph node metastasis in gastric cancer patients undergoing curative treatment. Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals. 2013;18(7):632-7.

25. Feng F, Tian Y, Xu G, Liu Z, Liu S, Zheng G, et al. Diagnostic and prognostic value of CEA, CA19-9, AFP and CA125 for early gastric cancer. BMC cancer. 2017;17(1):737.

26. Petrelli F, Cabiddu M, Coinu A, Borgonovo K, Ghilardi M, Lonati V, et al. Prognostic role of lactate dehydrogenase in solid tumors: a systematic review and meta-analysis of 76 studies. Acta oncolologica (Stockholm, Sweden). 2015;54(7):961-70.

27. Fanotto V, Cordio S, Pasquini G, Fontanella C, Rimassa L, Leone F, et al. Prognostic factors in 868 advanced gastric cancer patients treated with second-line chemotherapy in the real world. Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association. 2017;20(5):825-33.

Tables

Table 1. Association between the subclassification of pT2 stage and clinicopathological characteristics of patients.
|                          | sMP            | dMP            | P value |
|--------------------------|----------------|----------------|---------|
| **Sex**                  |                |                |         |
| male                     | 146/185(78.9%) | 149/195(76.4%) | 0.557   |
| female                   | 39/185(21.1%)  | 46/195(23.6%)  |         |
| **Age**                  |                |                |         |
| ≤60                      | 73/185(39.5%)  | 83/195(42.6%)  | 0.539   |
| >60                      | 112/185(60.5%) | 112/195(57.4%) |         |
| **Smoking history**      |                |                |         |
| No                       | 109/185(58.9%) | 104/195(53.3%) | 0.273   |
| Yes                      | 76/185(41.1%)  | 91/195(46.7%)  |         |
| **Drinking history**     |                |                |         |
| No                       | 111/185(60.0%) | 113/195(57.9%) | 0.685   |
| Yes                      | 74/185(40.0%)  | 82/195(42.1%)  |         |
| **ECOG score**           |                |                |         |
| 0                        | 129/185(69.7%) | 122/195(62.6%) | 0.334   |
| 1                        | 42/185(22.7%)  | 54/195(27.7%)  |         |
| 2                        | 14/185(7.6%)   | 19/195(9.7%)   |         |
| **Primary location**     |                |                |         |
| Upper                    | 83/185(44.9%)  | 92/195(47.2%)  | 0.896   |
| Middle                   | 24/185(13.0%)  | 25/195(12.8%)  |         |
| Low                      | 78/185(42.2%)  | 78/195(40.0%)  |         |
| **Bormann type**         |                |                |         |
| Type I-II                | 150/185(81.1%) | 157/195(80.5%) | 0.888   |
| Type III-IV              | 35/185(18.9%)  | 38/195(19.5%)  |         |
| **Pathological type**    |                |                |         |
| Adenocarcinoma           | 134/185(72.4%) | 146/195(74.9%) | 0.589   |
| Mucinous/rare carcinoma  | 51/185(27.6%)  | 49/195(25.1%)  |         |
| **Histologic type**      |                |                |         |
| Well and moderate        | 53/185(28.6%)  | 54/195(27.7%)  | 0.836   |
|                          | Group A (n=185) | Group B (n=195) | p-value |
|--------------------------|-----------------|-----------------|---------|
| **Neural invasion**      |                 |                 |         |
| Negative                 | 174/185(94.1%)  | 168/195(86.2%)  | 0.01    |
| Positive                 | 11/185(5.9%)    | 27/195(13.8%)   |         |
| **Lymphovascular invasion** |               |                 |         |
| Negative                 | 162/185(87.6%)  | 163/195(83.6%)  | 0.271   |
| Positive                 | 23/185(12.4%)   | 32/195(16.4%)   |         |
| **pN stage**             |                 |                 |         |
| N0                       | 121/185(65.4%)  | 110/195(56.4%)  | 0.205   |
| N1                       | 38/185(20.5%)   | 45/195(23.1%)   |         |
| N2                       | 19/185(10.3%)   | 25/195(12.8%)   |         |
| N3                       | 7/185(3.8%)     | 15/195(7.7%)    |         |
| **Number of lymph node metastasis*** | 1.0±2.1 | 1.6±2.7 | 0.027 |
| **TNM stage**            |                 |                 |         |
| I                        | 121/185(65.4%)  | 110/195(56.4%)  | 0.105   |
| II                       | 57/185(30.8%)   | 70/195(35.9%)   |         |
| IIIA                     | 7/185(3.8%)     | 15/195(7.7%)    |         |
| **Number of lymph node retrieved*** | 14.7±6.8 | 14.5±6.7 | 0.889 |
| **Adjuvant chemotherapy** |                 |                 |         |
| Without                  | 107/185(57.8%)  | 98/195(50.3%)   | 0.138   |
| With                     | 78/185(42.2%)   | 97/195(49.7%)   |         |
| **HER-2/neu expression** |                 |                 |         |
| Negative                 | 152/185(82.2%)  | 151/195(77.4%)  | 0.252   |
| Positive                 | 33/185(17.8%)   | 44/195(22.6%)   |         |
| **P53 expression**       |                 |                 |         |
| Negative                 | 89/185(48.1%)   | 82/195(42.1%)   | 0.236   |
| Positive                 | 96/185(51.9%)   | 113/195(57.9%)  |         |
|                  | Negative                  | Positive                  | p-value |
|------------------|---------------------------|---------------------------|---------|
| **VEGF expression** | 55/185 (29.7%)            | 49/195 (25.1%)            | 0.315   |
| **EGFR expression** | 65/185 (35.1%)            | 58/195 (29.7%)            | 0.262   |
| **initial LDH level (U/L)** | 179/185 (96.8%)         | 190/195 (97.4%)             | 0.693   |
| ≤245             | 179/185 (96.8%)            | 190/195 (97.4%)            |         |
| ≥245             | 6/185 (3.2%)               | 5/195 (2.6%)               |         |
| **maximal LDH level (U/L)** | 96/185 (51.9%)           | 115/195 (59.0%)            | 0.165   |
| ≤245             | 96/185 (51.9%)             | 115/195 (59.0%)            |         |
| ≥245             | 89/185 (48.1%)             | 80/195 (41.0%)             |         |
| **initial CEA level (ng/mL)** | 143/185 (77.3%)         | 141/195 (72.3%)            | 0.263   |
| ≤3.5             | 143/185 (77.3%)            | 141/195 (72.3%)            |         |
| ≥3.5             | 42/185 (22.7%)             | 54/195 (27.7%)             |         |
| **initial CA125 level (U/mL)** | 179/185 (96.8%)         | 193/195 (99.0%)            | 0.132#  |
| ≤35              | 179/185 (96.8%)            | 193/195 (99.0%)            |         |
| ≥35              | 6/185 (3.2%)               | 2/195 (1.0%)               |         |
| **initial CA19-9 level (U/mL)** | 179/185 (96.8%)         | 182/195 (93.3%)            | 0.126   |
| ≤39              | 179/185 (96.8%)            | 182/195 (93.3%)            |         |
| ≥39              | 6/185 (3.2%)               | 13/195 (6.7%)              |         |
| **initial AFP level (ng/mL)** | 181/185 (97.8%)         | 178/195 (91.3%)            | 0.005   |
| ≤7               | 181/185 (97.8%)            | 178/195 (91.3%)            |         |
| ≥7               | 4/185 (2.2%)               | 17/195 (8.7%)              |         |

Notes: *Two-tailed t tests of mean SD. #Two-sided Fisher’s exact test, others are two sided χ² test.

Table 2. Univariate and multivariate analyses of overall survival according to clinicopathologic factors.
|                                | Univariate analysis | Multivariate analysis |
|--------------------------------|---------------------|-----------------------|
|                                | HR (95% CI)         | P value               | HR (95% CI)         | P value          |
| **Sex**                        |                     |                       |                     |                  |
| Male vs female                 | 1.014 (0.616-1.669) | 0.957                 |                     |                  |
| **Age**                        |                     |                       |                     |                  |
| 60 vs ≥60                      | 2.047 (1.280-3.274) | 0.003                 | 2.075 (1.261-3.414) | 0.004            |
| **Smoking history**            |                     |                       |                     |                  |
| No vs yes                      | 1.119 (0.737-1.700) | 0.598                 |                     |                  |
| **Drinking history**           |                     |                       |                     |                  |
| No vs yes                      | 0.863 (0.562-1.325) | 0.500                 |                     |                  |
| **Primary location**           |                     |                       |                     |                  |
| Upper                          | 1.000               | 0.005                 | 1.000               | 0.002            |
| Middle                         | 1.020 (0.565-1.844) |                       | 0.985 (0.509-1.909) |                  |
| Low                            | 0.456 (0.279-0.746) |                       | 0.400 (0.235-0.680) |                  |
| **Borrmann type**              |                     |                       |                     |                  |
| Type I-II vs III-IV            | 1.482 (0.898-2.445) | 0.124                 |                     |                  |
| **Pathological type**          |                     |                       |                     |                  |
| Adenocarcinoma vs mucinous/rare carcinoma | 0.959 (0.596-1.544) | 0.864                 |                     |                  |
| **Histologic type**            |                     |                       |                     |                  |
| Well/moderate vs poor          | 1.163 (0.723-1.871) | 0.534                 |                     |                  |
| **Neural invasion**            |                     |                       |                     |                  |
| Negative vs positive           | 1.912 (1.080-3.388) | 0.026                 | 1.695 (0.915-3.141) | 0.093            |
| **Lymphovascular invasion**    |                     |                       |                     |                  |
|                                | sMP vs dMP | pN stage | Adjuvant chemotherapy |
|--------------------------------|------------|----------|-----------------------|
| **Negative vs positive**       | 1.526 (0.899-2.592) | 0.117    |                       |
| **Depth of tumor invasion**    | 1.805 (1.166-2.796) | 0.008    | 1.584 (1.000-2.509)   | 0.050   |
| **pN stage**                   |            |          |                       |
| N0                             | 1.000      | 0.000    | 1.000                 | 0.000   |
| N1                             | 2.543 (1.542-4.193) | 2.304 (1.364-3.890) |
| N2                             | 2.558 (1.393-4.698) | 1.879 (0.967-3.652) |
| N3                             | 4.948 (2.502-9.787) | 5.335 (2.533-11.237) |
| **Adjuvant chemotherapy**      |            |          |                       |
| Without vs With                | 0.890 (0.583-1.360) | 0.591    |                       |
| **HER-2/neu expression**       |            |          |                       |
| Negative vs positive           | 0.996 (0.593-1.672) | 0.987    |                       |
| **P53 expression**             |            |          |                       |
| Negative vs positive           | 2.288 (1.440-3.637) | 0.000    | 1.793 (1.117-2.879)   | 0.016   |
| **VEGF expression**            |            |          |                       |
| Negative vs positive           | 1.069 (0.647-1.768) |          | 0.794                |
| **EGFR expression**            |            |          |                       |
| Negative vs positive           | 0.919 (0.586-1.441) |          | 0.712                |
| **Initial LDH level (U/L)**    |            |          |                       |
| 245 vs ≥245                    | 1.230 (0.389-3.890) |          | 0.725                |
| **Maximal LDH level (U/L)**    |            |          |                       |
| 245 vs ≥245                    | 1.443 (0.950-2.193) | 0.086    | 1.688 (1.066-2.672)   | 0.025   |
| **Initial CEA level (ng/mL)**  |            |          |                       |
| 3.5 vs ≥3.5                    | 1.664 (1.071-2.207) | 0.024    | 0.987 (0.617-0.955)   | 0.955   |
| Initial CA125 level (U/mL) |    |    |
|---------------------------|----|----|
| 35 vs ≥35                 | 1.649 (0.521-5.218) | 0.394 |

| Initial CA19-9 level (U/mL) |    |    |    |
|-----------------------------|----|----|----|
| 39 vs ≥39                   | 2.450 (1.229-4.883) | 0.011 | 3.572 (1.735-7.358) | 0.001 |

| Initial AFP level (ng/mL)   |    |    |    |
|-----------------------------|----|----|----|
| 7 vs ≥7                     | 2.387 (1.235-4.614) | 0.010 | 2.033 (1.004-4.116) | 0.049 |

Notes: CI=confidence interval, HR=hazard ratio.

**Figures**
Figure 1

Flow diagram of the patient selection process.
Figure 2

Comparison of the survival outcomes for patients with sMP and dMP gastric cancers.

Log-rank $P=0.007$

HR = 0.56, 95%CI (0.37-0.86)

Figure 3

Log-rank $P=0.014$

HR = 0.43, 95%CI (0.22-0.85)

Log-rank $P=0.384$

HR = 0.79, 95%CI (0.46-1.35)
Survival curves of pT2 cancers according to the pN0 staging and pN+ staging, respectively. A) For patients with pN0 stage tumor, prognosis of the sMP group were significantly different with that of the dMP group (P=0.014). B) For patients with pN+ stage tumor, prognosis of the sMP group were not significantly different with that of the dMP group (P=0.384).

Figure 4

Survival curves of gastric cancer patients in dMP,N0 group and sMP,N1-2 group according to the adjuvant chemotherapy status, respectively. A) The survival outcome of patients were not significantly different between dMP,N0 group and sMP,N1-2 group (P=0.100). B) The survival outcome of patients with and without adjuvant chemotherapy were significant difference in dMP,N0 group (P=0.045). In comparison to patients in sMP,N1-2 group, patients in dMP,N0 group who accepted adjuvant chemotherapy had better postoperative survival (P=0.015) (C), but not significance in that without adjuvant chemotherapy (P=0.599) (D).
Figure 5

Survival curves of gastric cancer patients in dMP,N0 group and T2,N1-2 group according to other potential prognosis factors, respectively. A) The survival outcome of sMP,N0 patients were better than dMP,N0 patients in p53-positive group (P=0.002). B) The survival outcome of patients in p53+,dMP,N0 group were not significantly different to patients in T2,N1-2 group (P=0.872). C) The survival outcome of sMP,N0 patients were greater than dMP,N0 patients in elevated maximal LDH level group (P=0.029). D) The
survival outcome of patients in elevated maximal LDH,dMP,N0 group were not significantly different to
patients in T2,N1-2 group (P=0.514). E) There were statistically better overall survival of sMP,N0 patients
than dMP,N0 patients in elevated initial CEA level group (P=0.011). F) The overall survival of patients in
elevated initial CEA,dMP,N0 group were similar to patients in T2,N1-2 group (P=0.935).